Guodong Cao

1.8k citations
48 papers · 1.3k indexed · 1 hit paper · h-index 19
Topics
Nanoplatforms for cancer theranostics (10 papers)Ferroptosis and cancer prognosis (6 papers)Cancer-related molecular mechanisms research (6 papers)
Partner nations
ChinaUnited StatesFrance

In The Last Decade

Guodong Cao

45 papers receiving 1.3k citations

Hit Papers

Co–Ferrocene MOF/Glucose Oxidase as Cascade Nanozyme for ...20202026202220242020100200300

Peers

Guodong Cao
Comparison fields: 5 of 107
  • Biomedical Engineering 513
  • Materials Chemistry 446
  • Molecular Biology 430
  • Oncology 237
  • Biomaterials 208
Replace Reza Akhavan‐Sigari with:
Reza Akhavan‐Sigari Germany
Lijuan Wen China
Benchen Rao China
Donato Colangelo Italy
Quancheng Kan China
Jinge Zhao China
Hariprasad Gali United States
Xiaoxue Xie China
Zhiwei Sun China
Guodong Cao relative to Reza Akhavan‐Sigari Germany Reza Akhavan‐Sigari's profile →
Citations per field
00.5×5.4×
Reza Akhavan‐Sigari · 1×
Citations per year

Countries citing papers authored by Guodong Cao

Since Specialization
Citations

This map shows the geographic impact of Guodong Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guodong Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guodong Cao more than expected).

Fields of papers citing papers by Guodong Cao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guodong Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guodong Cao. The network helps show where Guodong Cao may publish in the future.

Co-authorship network of co-authors of Guodong Cao

This figure shows the co-authorship network connecting the top 25 collaborators of Guodong Cao. A scholar is included among the top collaborators of Guodong Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guodong Cao. Guodong Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 5
3 7
4 8
5 4
6 11
7 7
8 13
9 3
10 51
11 24
12 109
13 19
14 7
15 13
16 9
17 4
18 3
19 9
20 65

About Guodong Cao

Guodong Cao is a scholar working on Cancer Research, Oncology and Biomaterials, having authored 48 papers that have together received 1.3k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (10 papers), Ferroptosis and cancer prognosis (6 papers) and Cancer-related molecular mechanisms research (6 papers). The work is most often cited by research in Biomaterials (208 citations), Cancer Research (202 citations) and Biomedical Engineering (513 citations). Guodong Cao has collaborated with scholars based in China, United States and France. Frequent co-authors include Xiang Li, Maoming Xiong, Qiang Chu, Gaorong Han, Chao Fang, Yulian Wu, Xinsheng Peng, Zheng Deng, Bo Chen and Xudong Feng. Their work appears in journals such as ACS Nano, PLoS ONE and Advanced Functional Materials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026